News

Net profit of Neuland Laboratories rose 962.37% to Rs 147.67 crore in the quarter ended June 2026 as against Rs 13.90 crore during the previous quarter ended June 2025. Sales rose 119.16% to Rs 641.58 crore in the quarter ended June 2026 as against Rs 292.75 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales641.58292.75 119 OPM %34.7411.78 - PBDT224.4137.76 494 PBT197.8517.57 1026 NP147.6713.90 962 Powered by Capital Market - Live News

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Neuland Laboratories has received affirmation in credit ratings for bank facilities at IND A+/ Positive / IND A1.

The board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the enhancement of capacity at its Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. Existing capacity - 256 KL Existing capacity utilization - 91% Proposed capacity addition - 120.5 KL Period for capacity addition - within 12-18 months Investment required - Rs 143.4 crore (funded through internal accruals and borrowings)

The board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the appointment of Dr. Mauricio Futran (DIN: 11699767) as an Additional Director of the Company, categorized as Non-Executive Non-Independent, w.e.f. 12 May 2026.